☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Shanghai Henlius
Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)
May 24, 2024
Accord BioPharma’s Hercessi (Biosimilar, Herceptin) Receives the US FDA Approval
April 29, 2024
Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)
April 8, 2024
Shanghai Henlius Reports P-III Placebo-Controlled Trial Results of HLX01 (biosimilar, rituximab) for Active Rheumatoid Arthritis
October 10, 2022
Load more...
Back to Home